Galvani Giuseppe, Fousteri Georgia
Giuseppe Galvani, Georgia Fousteri, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
World J Diabetes. 2017 Jul 15;8(7):330-336. doi: 10.4239/wjd.v8.i7.330.
An allelic variant of the protein tyrosin phosphatase non-receptor 22 () gene, PTPN22 R620W, constitutes the strongest non-HLA genetic risk factor for the development of type 1 diabetes (T1D). A number of studies using mouse models have addressed how PTPN22 predisposes to T1D. PTPN22 downmodulation, overexpression or expression of the variant gene in genetically manipulated mice has generated controversial results. These discrepancies probably derive from the fact that PTPN22 has differential effects on innate and adaptive immune responses. Moreover, the effects of PTPN22 are dependent on other genetic variables. Here we discuss these findings and try to explain the discrepancies. Exploring the mechanism by which PTPN22 contributes to islet-specific autoimmunity could help us understand its role in T1D pathogenesis and exploit it as a potential therapeutic target to prevent the disease.
蛋白酪氨酸磷酸酶非受体22(PTPN22)基因的一个等位基因变体PTPN22 R620W,是1型糖尿病(T1D)发生发展最强的非HLA遗传风险因素。多项使用小鼠模型的研究探讨了PTPN22如何导致T1D。在基因操作小鼠中对PTPN22进行下调、过表达或变体基因表达已产生了有争议的结果。这些差异可能源于PTPN22对先天性和适应性免疫反应有不同影响这一事实。此外,PTPN22的作用取决于其他遗传变量。在此我们讨论这些发现并试图解释这些差异。探索PTPN22促成胰岛特异性自身免疫的机制,可能有助于我们理解其在T1D发病机制中的作用,并将其作为预防该疾病的潜在治疗靶点加以利用。